Update on hepatitis C virus management
- PMID: 40227981
- DOI: 10.1097/MOG.0000000000001098
Update on hepatitis C virus management
Abstract
Purpose of review: Despite the efficacy of direct-acting antiviral (DAA) therapy, hepatitis C virus (HCV) remains a significant contributor to liver-related morbidity and mortality. This review summarizes the approach to HCV treatment, the simplified treatment algorithm for most patients, the management of special populations, and future directions for HCV interventions.
Recent findings: Pan genotypic DAA regimens have high cure rates and can be managed by nonspecialist providers, and the simplified treatment approach provides a clear algorithm for workup and treatment decisions among treatment-naive patients without decompensated cirrhosis. Additionally, advancements in point of care diagnostics have the potential to further expand access to screening and linkage to care. Despite these breakthroughs, barriers to accessing care and the stigmatization of high-risk populations continue to undercut progress towards HCV elimination. Continued implementation of innovative screening and treatment strategies are required to overcome rising HCV prevalence.
Summary: HCV cure is achievable for nearly all patients, but reaching HCV elimination goals will require a comprehensive approach that increases screening, expands access to simplified treatment, and avoids stigmatization of at-risk populations. Targeting healthcare disparities and removing barriers to treatment uptake are crucial to achieving elimination targets.
Keywords: direct-acting antivirals; hepatitis C virus; hepatitis C virus elimination; simplified hepatitis C virus treatment algorithm.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.J Gen Intern Med. 2022 Oct;37(13):3435-3443. doi: 10.1007/s11606-022-07628-9. Epub 2022 Apr 28. J Gen Intern Med. 2022. PMID: 35484367 Free PMC article. Review.
-
Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.World J Gastroenterol. 2022 Jan 14;28(2):263-274. doi: 10.3748/wjg.v28.i2.263. World J Gastroenterol. 2022. PMID: 35110949 Free PMC article.
-
Hepatitis C.Lancet. 2023 Sep 23;402(10407):1085-1096. doi: 10.1016/S0140-6736(23)01320-X. Lancet. 2023. PMID: 37741678 Review.
-
Cost effectiveness of hepatitis C direct acting agents.Expert Rev Pharmacoecon Outcomes Res. 2024 Jun;24(5):589-597. doi: 10.1080/14737167.2024.2348053. Epub 2024 May 3. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38665122 Review.
-
Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.Lancet. 2019 Mar 30;393(10178):1319-1329. doi: 10.1016/S0140-6736(18)32277-3. Epub 2019 Jan 29. Lancet. 2019. PMID: 30704789 Free PMC article.
References
-
- Polaris Observatory HCVC. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022; 7:396–415.
-
- Ogawa E, Chien N, Kam L, et al. Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C. JAMA Intern Med 2023; 183:97–105.
-
- Wester C, Osinubi A, Kaufman HW, et al. Hepatitis C virus clearance cascade - United States, 2013-2022. MMWR Morb Mortality Wkly Rep 2023; 72:716–720.
-
- Jeong D, Wong S, Karim ME, et al. Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada. Lancet Reg Health Am 2024; 29:100658.
-
- Force USPST, Owens DK, Davidson KW, et al. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA 2020; 323:970–975.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials